Significant Association of Serum Adiponectin and Creatine Kinase-MB Levels in ST-Segment Elevation Myocardial Infarction

Aims: Adiponectin, an adipocyte-specific secretory protein, abundantly exists in the blood stream while its concentration paradoxically decreases in obesity. Hypoadiponectinemia is one of risks of cardiovascular diseases. However, impact of serum adiponectin concentration on acute ischemic myocardial damages has not been fully clarified. The present study investigated the association of serum adiponectin and creatine kinase (CK)-MB levels in subjects with ST-segment elevation myocardial infarction (STEMI). Methods: This study is a physician-initiated observational study and is also registered with the University Hospital Medical Information Network (Number: UMIN 000014418). Patients were admitted to Senri Critical Care Medical Center, given a diagnosis of STEMI, and treated by primary percutaneous coronary intervention (PCI). Finally, 49 patients were enrolled and the association of serum adiponectin, CK-MB, and clinical features were mainly analyzed. Results: Serum adiponectin levels decreased rapidly and reached the bottom at 24 hours after recanalization. Such reduction of serum adiponectin was inversely correlated with the area under the curve (AUC) of serum CK-MB (p = 0.013). Serum adiponectin concentrations were inversely correlated with AUC of serum CK-MB. In multivariate analysis, serum adiponectin concentration on admission (p = 0.002) and collateral (p = 0.037) were significantly and independently correlated with serum AUC of CK-MB. Conclusion: Serum AUC of CK-MB in STEMI subjects was significantly associated with serum adiponectin concentration on admission and reduction of serum adiponectin levels from baseline to bottom. The present study may provide a possibility that serum adiponectin levels at acute phase are useful in the prediction for prognosis after PCI-treated STEMI subjects.

[1]  N. Ouchi Adipocytokines in Cardiovascular and Metabolic Diseases. , 2016, Journal of atherosclerosis and thrombosis.

[2]  T. Kitamoto,et al.  CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass. , 2016, Journal of atherosclerosis and thrombosis.

[3]  H. Selker,et al.  Serum adiponectin levels in patients with acute coronary syndromes: Serial changes and relation to infarct size , 2015, Diabetes & vascular disease research.

[4]  L. Hsu,et al.  Association of CDH13 Genotypes/Haplotypes with Circulating Adiponectin Levels, Metabolic Syndrome, and Related Metabolic Phenotypes: The Role of the Suppression Effect , 2015, PloS one.

[5]  J. Marinković,et al.  Time-dependent changes of plasma adiponectin concentration in relation to coronary microcirculatory function in patients with acute myocardial infarction treated by primary percutaneous coronary intervention. , 2015, Journal of cardiology.

[6]  T. Funahashi,et al.  Positive feedback regulation between adiponectin and T-cadherin impacts adiponectin levels in tissue and plasma of male mice. , 2015, Endocrinology.

[7]  M. Kals,et al.  CDH13 promoter SNPs with pleiotropic effect on cardiometabolic parameters represent methylation QTLs , 2014, Human Genetics.

[8]  P. Armstrong,et al.  Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. , 2014, American heart journal.

[9]  T. Funahashi,et al.  A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study , 2014, Cardiovascular Diabetology.

[10]  A. Baumbach,et al.  Infarct size reduction in acute myocardial infarction , 2014, Heart.

[11]  Yukiko Nakamura,et al.  Ultrastructural Localization of Adiponectin protein in Vasculature of Normal and Atherosclerotic mice , 2014, Scientific Reports.

[12]  Y. Teo,et al.  Genetic Variation in CDH13 Is Associated With Lower Plasma Adiponectin Levels but Greater Adiponectin Sensitivity in East Asian Populations , 2013, Diabetes.

[13]  S. Kihara,et al.  Adiponectin Protein Exists in Aortic Endothelial Cells , 2013, PloS one.

[14]  Ryosuke Kikuchi,et al.  T-cadherin Is Essential for Adiponectin-mediated Revascularization* , 2013, The Journal of Biological Chemistry.

[15]  T. Funahashi,et al.  Cardiovascular-metabolic impact of adiponectin and aquaporin. , 2013, Endocrine journal.

[16]  J. Jordan,et al.  Atrial Natriuretic Peptide and Adiponectin Interactions in Man , 2012, PloS one.

[17]  Y. Kokubo,et al.  CDH13 gene coding t‐cadherin influences variations in plasma adiponectin levels in the Japanese population , 2012, Human mutation.

[18]  I. Shimomura,et al.  Induced Adipocyte Cell-Sheet Ameliorates Cardiac Dysfunction in a Mouse Myocardial Infarction Model: A Novel Drug Delivery System for Heart Failure , 2011, Circulation.

[19]  Wen-Harn Pan,et al.  A Genome-Wide Association Study Reveals a Quantitative Trait Locus of Adiponectin on CDH13 That Predicts Cardiometabolic Outcomes , 2011, Diabetes.

[20]  W. Koch,et al.  Downregulation of adiponectin induced by tumor necrosis factor &agr; is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury* , 2011, Critical care medicine.

[21]  P. Buszman,et al.  Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. , 2011, International journal of molecular medicine.

[22]  P. Ruiz-Lozano,et al.  T-cadherin is critical for adiponectin-mediated cardioprotection in mice. , 2010, The Journal of clinical investigation.

[23]  M. Matsuzaki,et al.  Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study. , 2010, Atherosclerosis.

[24]  T. Murohara,et al.  Impact of a Single Intracoronary Administration of Adiponectin on Myocardial Ischemia/Reperfusion Injury in a Pig Model , 2010, Circulation. Cardiovascular interventions.

[25]  T. Funahashi,et al.  Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. , 2009, Journal of the American College of Cardiology.

[26]  Jonathan C. Cohen,et al.  Genome‐wide Linkage and Association Analyses to Identify Genes Influencing Adiponectin Levels: The GEMS Stud , 2009, Obesity.

[27]  S. Kihara,et al.  Usefulness of adiponectin to predict myocardial salvage following successful reperfusion in patients with acute myocardial infarction. , 2008, The American journal of cardiology.

[28]  S. Kihara,et al.  Adiponectin Protects Against Angiotensin II–Induced Cardiac Fibrosis Through Activation of PPAR-&agr; , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[29]  J. Ottervanger,et al.  Prognostic importance of creatine kinase and creatine kinase-MB after primary percutaneous coronary intervention for ST-elevation myocardial infarction. , 2008, American heart journal.

[30]  A. Hirayama,et al.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2007, The Lancet.

[31]  S. Kihara,et al.  Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. , 2007, Cardiovascular research.

[32]  Walter Koch,et al.  Adiponectin Cardioprotection After Myocardial Ischemia/Reperfusion Involves the Reduction of Oxidative/Nitrative Stress , 2007, Circulation.

[33]  S. Kihara,et al.  Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. , 2006, Kidney international.

[34]  Kazuo Kimura,et al.  Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. , 2006, Journal of the American College of Cardiology.

[35]  G. Stone,et al.  Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. , 2006, Journal of the American College of Cardiology.

[36]  S. Kihara,et al.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms , 2005, Nature Medicine.

[37]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[38]  熊田 全裕 Association of hypoadiponectinemia with coronary artery disease in men , 2004 .

[39]  S. Kihara,et al.  Adiponectin and Metabolic Syndrome , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[40]  S. Kihara,et al.  Erratum , 2003, Heart.

[41]  S. Kihara,et al.  Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[42]  M. Matsuda,et al.  Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. , 2002, Diabetes.

[43]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell , 2002, Circulation.

[44]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[45]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001, Circulation.

[46]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[47]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[48]  M. Cohen,et al.  Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. , 1985, Journal of the American College of Cardiology.

[49]  C. W. Small,et al.  Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction. , 1975, Circulation.

[50]  T. Funahashi,et al.  Adiponectin and the cardiometabolic syndrome: an epidemiological perspective. , 2014, Best practice & research. Clinical endocrinology & metabolism.

[51]  T. Funahashi,et al.  Cardiovascular-metabolic impact of adiponectin and aquaporin [Review] , 2013 .

[52]  M. Matsuda,et al.  Effect of pravastatin on the development of diabetes and adiponectin production. , 2008, Atherosclerosis.

[53]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.